28.10.2025
An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 11 November 2025 at 10:00 (CET), as a digital meeting.
The agenda of the meeting is election of a new auditor for the Company. The elected auditor, PwC, has informed Arctic Bioscience AS of corporate reorganization that will result in a portion of their business, including partners, employees and clients, being moved to a wholly owned subsidiary. Arctic Bioscience AS is one of the clients that has been moved to the wholly owned subsidiary. The move does not entail any changes to the services provided. The reorganization of PwC therefore only has the practical effect that PwC’s subsidiary, PwC Assurance AS, must be elected as auditor instead of PwC AS. See notice for more information.
Shareholders are encouraged to cast their votes in advance of the General Meeting or grant the Chair of the Board a proxy, with or without voting instructions.
Deadline for registration of attendance, advance votes, proxy or instructions is 7 November 2025 at 16:00 (CET). For attendance to the live event, please follow the instructions in the notice.
For further information, see the attached Notice of the Extraordinary General Meeting, which can also be accessed from the company’s website (https://arctic-bioscience.com/investors/general-meetings/).
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.